Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.40)
# 3,939
Out of 4,760 analysts
42
Total ratings
17.24%
Success rate
-28.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $1.73 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $14.60 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $43.34 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $22.39 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $71.13 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $31.99 | - | 4 | Dec 18, 2024 | |
| TNGX Tango Therapeutics | Reiterates: Overweight | n/a | $1.86 | - | 3 | Dec 5, 2024 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $4.85 | - | 3 | Nov 14, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | n/a | $15.36 | - | 1 | Oct 8, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $30.04 | +219.57% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.94 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.50 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.00 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $150.71 | +93.75% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $500.01 | -26.00% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.56 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.49 | - | 1 | May 30, 2017 |
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.73
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $14.60
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $43.34
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $22.39
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $71.13
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.99
Upside: -
Tango Therapeutics
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.86
Upside: -
Alumis
Nov 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.85
Upside: -
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: n/a
Current: $15.36
Upside: -
Avidity Biosciences
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $30.04
Upside: +219.57%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.94
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.50
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $150.71
Upside: +93.75%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $500.01
Upside: -26.00%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.56
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.49
Upside: -